Evidence map›Paper›PMID 35782122›Full record

ReviewFrontiers in cellular and infection microbiology2022

The State-of-the-Art of Gene Editing and its Application to Viral Infections and Diseases Including COVID-19.

Yousef M Hawsawi, Anwar Shams, Abdulrahman Theyab, Jumana Siddiqui, Mawada Barnawee, Wed A Abdali, Nada A Marghalani, Nada H Alshelali, Rawan Al-Sayed, Othman Alzahrani and 2 more

Abstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yousef M HawsawiResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Anwar ShamsDepartment of Pharmacology, College of Medicine, Taif University, Mecca, Saudi Arabia.
Abdulrahman TheyabCollege of Medicine, Al-Faisal University, Riyadh, Saudi Arabia.
Jumana SiddiquiResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Mawada BarnaweeResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Wed A AbdaliResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Nada A MarghalaniResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Nada H AlshelaliResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Rawan Al-SayedResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Othman AlzahraniDepartment of Biology, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Alanoud AlqahtaniBristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom.
Abdulrahman M AlsulaimanDepartment of Medical Microbiology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy delivers a promising hope to cure many diseases and defects. The discovery of gene-editing technology fueled the world with valuable tools that have been employed in various domains of science, medicine, and biotechnology. Multiple means of gene editing have been established, including CRISPR/Cas, ZFNs, and TALENs. These strategies are believed to help understand the biological mechanisms of disease progression. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been designated the causative virus for coronavirus disease 2019 (COVID-19) that emerged at the end of 2019. This viral infection is a highly pathogenic and transmissible disease that caused a public health pandemic. As gene editing tools have shown great success in multiple scientific and medical areas, they could eventually contribute to discovering novel therapeutic and diagnostic strategies to battle the COVID-19 pandemic disease. This review aims to briefly highlight the history and some of the recent advancements of gene editing technologies. After that, we will describe various biological features of the CRISPR-Cas9 system and its diverse implications in treating different infectious diseases, both viral and non-viral. Finally, we will present current and future advancements in combating COVID-19 with a potential contribution of the CRISPR system as an antiviral modality in this battle.

Indexed as

COVID-19Virus DiseasesGene EditingHumansPandemicsSARS-CoV-2COVID-19CRISPR/Cas9gene editingvaccinesviral infection

Identifiers

PMID35782122
PMCPMC9241565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.